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Cervical cancer is a common cancer inﬂicting women worldwide. Even though, persistent infection with oncogenic Human
Papillomavirus (HPV) types is considered the most important risk factor for cervical cancer development, less than 5% of women
with HPV will eventually develop cervical cancer supporting thatother molecular events,likemethylation-dependent inactivation
of tumor suppressor genes, may cocontribute in cervical carcinogenesis. We analyzed promoter methylation of three candidate
genes (p16,MGMT,andhMLH1) in 403liquid-based cytology samples.Methylation wascommonlyidentiﬁed in both benign and
pathologicsamplesand correlated withhigher lesiongrade determined by cytological, colposcopical,or histologicalﬁndings,with
HPV DNA and mRNA positivity of speciﬁc HPV types and p16INK4A protein expression. Overall accuracy of methylation is much
lower than traditional diagnostic tests ranking it as an ancillary technique with more data needed to identify the exact value of
methylation status in cervical carcinogenesis.
1.Introduction
Cervical cancer still remains the third most commonly
diagnosed cancer type in women worldwide, particularly
in developing countries, with over 500,000 estimated new
cases and over 250,000 estimated deaths [1]. The main cause
of cervical cancer development is infection with Human
Papilloma Viruses (HPVs) [2], that are small DNA viruses
withoncogenicproperties[3–5].There are over100diﬀerent
HPV types, but only around 40 have been found in cervical
epithelium and about 20 have been considered as high-
risk factors for cancer development [6, 7]. Even though,
persistent infection with oncogenic Human Papillomavirus
(HPV) types is considered the most important risk factor for
cervical cancer development, less than 5% of women with
HPV will eventually develop cervical cancer [8], supporting
the notion that other molecular events cocontribute in
cervical carcinogenesis.
Inactivation of tumor suppressor genes has been shown
to be a critical step in tumor development [9]. Apart from
well-monitored suppressionmechanisms asmutationalinac-
tivation, chromosome deletions, and loss of heterozygosity,
epigenetic inactivation of tumor suppressor genes is a more
recent discovery, where promoter methylation of a tumor
suppressor gene abolishes its expression [10]. A signiﬁcant
amount of studies have provided evidence that promoter
methylationoftumorsuppressorgenesislinkedwithcervical
carcinogenesis [11–13] and even with speciﬁc severity of
lesions [14].2 Infectious Diseases in Obstetrics and Gynecology
Methylation-speciﬁc PCR (MSP) is a sensitive technique
widely used to identify promoter methylation, mainly due to
its low cost [15]. With MSP, promoter methylation has been
discovered in various tumor suppressor genes connected
withcellcycleregulationasp16INK4A andDNArepairmecha-
nisms as human MutL Homolog 1 (hMLH1) and O6-Meth-
ylguanineDNAMethylTransferase(MGMT)[11,13,16,17].
p16INK4A is a protein shown to be overexpressed in high-
gradelesionsasaresultofHPVoncoproteinover-expression,
while inhibition of DNA repair mechanisms has been shown
to occur in many types of carcinomas [4, 5, 9, 13].
In this study we used MSP to identify promoter methy-
lation of the three above referred tumor suppressor genes in
normal and pathological cervical liquid-based cytology sam-
ples,in orderto evaluatetheiruse in identifying lesions. Next
we assessed the relation of promoter methylation to HPV
presence, mRNA expression, p16INK4A protein expression,
and clinicopathological features, in order to clarify whether
methylation is correlated with HPV presence and lesion
progression.
2.Materialsand Methods
2.1.Specimens. Sampleswere part ofa largerpoolofsamples
from primary screening for cervical cancer in Greece. A total
of 403 liquid-based cytological (LBC) smears from women
that underwent colposcopy were included in the present
study. These consisted of 340 histologically conﬁrmed sam-
ples and 63 samples with normal cytology that were added
in order to increase the number of cytologically negative
samples and have a better baseline of promoter methylation
in “normal” samples. The study population consisted of
women with a mean of 36.8 years of age (min–max: 18–
81), a start of sexual intercourse at 18.9 years of age (13–
30), and with a mean of 3.9 sexual partners (1–16). Cytology
smears were collected in liquid-based media (ThinPrep,
Hologic, Marlborough, USA), a single-layer smear was pre-
pared by automated means (TP2000 processor), stained
according to Papanikolaou, and diagnosis was set according
to the Bethesda system by a skilled cytopathologist [18]. All
molecular tests were performed on residual LBC specimens.
Histology diagnosis was set by a skilled histopathologist and
for statistical purposes CIN-I were classiﬁed as LSIL, while
CINII and CINIII were classiﬁed as HSILs.
2.2. Bisulﬁte Conversion MSP. A commercially available kit
for bisulfate conversion and PCR ampliﬁcation was used
(Amplicolon, Bird Srl, Siena, Italy) to identify promoter
methylation of p16INK4A, hMLH1, and MGMT. PCR prod-
uctswere analyzedina2%agarose gel,stainedwithethidium
bromide and visualized under UV light. If a PCR product
was detected only in the unmethylated reaction, sample was
characterized as unmethylated, while presence of a PCR
product in the methylated reaction characterized the sample
as methylated, regardless of the result of the unmethylated
reaction. Absence of a product from both reactions charac-
terized the sample as invalid. An unmethylated DNA control
is included in the kit, while a methylated DNA control was
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Figure 1: Agarose gel electrophoresis of PCR products of gene pro-
moter methylation of (a) MGMT, (b) hMLH1, and (c) p16INK4A.L :
DNA ladder 50bp, +ctl: DNA treated with SssI, −ctl: unmethylated
DNA control, s1,s2: clinical samples negative for methylation for
MGMT and hMLH1. s2 is positive for p16 methylation.
created after treatment ofthe unmethylated control with SssI
methyltransferase (NEB,Massachusetts, USA)(seeFigure 1).
2.3. HPV Typing and E6/E7 mRNA Expression. DNA HPV
typing was performed using a commercially available kit
(CLART HPV2, Genomica, Madrid, Spain), according to
manufacturer’s instructions. The kit can identify 35 diﬀerent
HPV types, that are categorized as low risk (HPVs 6, 11, 40,
42, 43, 44, 54, 61, 62, 71, 72, 81, 83, 84, and 89) and high
risk (HPVs 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58,
59, 66, 68, 70, 73, 82, and 85) based on their epidemiology
in speciﬁc grade of lesions [6]. E6/E7 mRNA expression
was identiﬁed using the commercially available Nuclisens
EasyQ HPV kit (Biomerieux SA, Marcy l’Etoile, France),
that is, able to detect mRNA of ﬁve high-risk HPV types
(HPV16,HPV18,HPV31,HPV33,andHPV45).Positiveand
no template controls were included in all experiments.
2.4. p16INK4A Protein Expression. Protein expression of
p16INK4A was identiﬁed by immunocytochemistry using a
commercial kit according to the manufacturer’s instructions
(CINtec Cytology, mtm Laboratories AG, Heidelberg, Ger-
many). Evaluation of positive staining was performed by an
experienced cytopathologist.
2.5. Statistical Analysis. All statistic tests were performed
using IBM Statistics SPSS 19 (IBM Corporation, NY, USA)
using χ2 analysis, two-paired t-test and bivariate correlation
analysis. All analysis tests were two tailed with signiﬁcance at
95%. Overall accuracy was estimated by ROC analysis using
histology (HSIL+) as the golden standard.
3.Resultsand Discussion
Promoter methylation status was successfully analyzed for
403 samples for MGMT, 372 samples for hMLH1 and 290
samples for p16INK4A.p 1 6 INK4A protein expression was avail-
able for 358 samples, HPV DNA typing for 398 samples and
mRNA expression for 355 samples. Cytological, colposcopi-
cal,andhistologicalﬁndingswerewellcorrelatedasindicated
by the area under the curve (AUC) values of both cytology
(0.863) and colposcopy (0.861) compared to histology.
3.1. Promoter Methylation and Clinicopathological Findings.
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Table 1: Promoter methylation results.
MGMT hMLH1 p16INK4A Any gene
M (%) N P M (%) N P M (%) NpM (%) N P
Cytology
WNL 22 22.7 97
∗∗∗
55 . 78 8
∗
7 13.5 52 31 32.0 97
∗∗∗
ASCUS 26 40.7 64 4 7.0 57 9 18.4 49 33 51.6 64
LgSIL 51 38.6 132 22 17.9 123 18 17.5 103 75 56.8 132
ASC-H 3 37.5 8 1 14.3 7 1 33.3 3 4 50.0 8
HgSIL 43 47.3 91 13 14.8 88 15 19.7 76 54 59.3 91
SCC 5 80.0 6 0 0 5 1 33.3 3 5 83.3 6
AdenoCa 5 100 5 2 50.0 4 3 75.0 4 5 100 5
Colposcopy
NSF 3 42.9 7
∗∗∗
00 7
∗
0 0 5 3 42.9 7
∗∗∗
Negative 25 27.2 93 6 7.3 82 11 21.2 52 35 38.0 93
LGSIL 74 38.7 191 24 13.6 177 25 17.6 142 100 52.4 191
HGSIL 40 40.8 98 15 16.1 93 15 18.5 81 56 57.1 98
SCC 9 81.8 11 1 10.0 10 1 14.3 7 9 81.8 11
AdenoCa 4 100 4 1 33.3 3 2 66.7 3 4 100 4
Histology
Negative 13 22.8 57
∗∗∗
8 15.1 53 5 12.2 41 21 36.8 57
∗∗
LSIL 70 42.7 164 21 13.5 155 25 20.7 121 95 57.9 164
HSIL 43 42.6 101 14 14.6 96 15 17.6 85 57 56.4 101
SCC 8 66.7 12 1 9.1 11 1 12.5 8 8 66.7 12
AdenoCa 6 100 6 2 40.0 5 3 75.0 4 6 100 6
M:M e t h y l a t e d ,N:N u m b e ro fc a s e s ,N S F :N o n s a t i s f a c t o r y ,χ2 for trend P: ∗P<. 05, ∗∗P<. 005, ∗∗∗P<. 001.
Table 1. MGMT methylation was the most aberrant methy-
lated gene, followed by p16INK4A and ﬁnally by hMLH1.
MGMT methylation increased statistically signiﬁcant with
lesion severity as determined by either cytological (P<
.0001),colposcopical (P<. 0001),or histological (P<. 0001)
ﬁndings.hMLH1methylation,ontheotherhand,displayeda
signiﬁcant increase with lesion severity only with cytological
(P = .0173) and colposcopical (P = .0489) ﬁndings, while
p16INK4A methylation showed no signiﬁcant diﬀerence. Any
of the three genes was statistically more often methylated
in more severe lesions, as determined by either cytological
(P<. 0001), colposcopical (P = .0002), or histological
(P = .0031) ﬁndings.
3.2. Promoter Methylation and Molecular/Immunocytochem-
ical Findings. Positivity of p16INK4A protein expression in-
creased with MGMT and p16INK4A methylation (P = .001
and P = .013). Methylation of MGMT increased with HPV
DNA positivity (P = .021), overall mRNA positivity (P =
.017), expression of HPV16 mRNA (P = .001), and DNA
positivityforHPV16,HPV18,andHPV68(P<. 01).hMLH1
methylation increased withpositivity for low-risk HPVDNA
(P = .001), HPV16 mRNA (P = .035) and DNA positivity
for HPV40, HPV51, and HPV61 (P<0.01). Methylation of
p16INK4A increased with overall mRNA positivity (P = .046),
expression of HPV16 mRNA (P = .05), HPV33 mRNA
(P = .036) HPV16, HPV43, and HPV85 DNA positivity.
Presence of either HPV16, HPV45, HPV53, HPV61, HPV68
DNA positivity or HPV16 and HPV45 mRNA positivity was
correlated with an increase of the number of methylated
genes (P<. 01).
3.3.HPVStatus, p16INK4A ProteinExpressionandClinicopath-
ological Findings. Severity of the lesion, whether determined
by cytology, colposcopy, or histology, was statistically higher
with p16INK4A protein expression, mRNA expression, and
presence of HPV DNA of high-risk types (P<. 001). HPV
DNA positivity could either be only from high-risk types or
mixed with low-risk types. Presence of low-risk HPV DNA
was only correlated with low grade lesions (P<. 01). HPV
DNA positivity was more common in younger women (35.5
versus 39.3, P = .003) with more sex partners (4.3 versus
2.8, P = .039), while p16INK4A protein expression was more
common in older women (39.6 versus 36.8, P = .04) with
earlier sex life initiation (17.8 versus 19.5, P = .019).
3.4. Discussion. Promoter methylation has been proposed
to be a signiﬁcant cofactor in carcinogenesis, especially in
nonhereditary carcinomas. Its role in epigenetic inactivation
of tumor suppressor genes has been shown to be common in
many types ofcarcinomas, while recentevidencesupports its
contribution in cancer development in the cervix [10–14].
Findings of this study, as far as promoter methylation
increase during lesion progression is concerned, are partially
consistent with previous studies [11, 12, 14, 19]. The main
diﬀerence with the present study is the signiﬁcantly larger
amountofsamplesthatareincludedinourstudyandthesig-
nificantly higher positivity rate of methylation in our study.
As far as diagnostic or screening utility of promoter methy-
lation, none of the genes displayed an AUC of over 0.6
when plotted against histology, with HSIL as the cutoﬀ,
ranking it as an ancillary technique with more data needed4 Infectious Diseases in Obstetrics and Gynecology
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Figure 2: ROC curve analysis. Diagonal segments are produced by
ties.
to identify the exact value of methylation status in cervical
carcinogenesis.
As expected HPV DNA testing displayed high sensitivity
with low speciﬁcity depicted in the ROC curve (Figure 2,
AUC 0.641), while mRNA higher speciﬁcity with lower
sensitivity (AUC 0.767). p16INK4A protein expression showed
displayed better speciﬁcity than mRNA testing, but worse
sensitivity (AUC 0.694). The above ﬁndings are consistent
with previous studies, that have shown the use of these
techniques in triaging women [6, 7, 20–23].
Presence of both p16INK4A protein expression and pro-
moter methylation was identiﬁed in both HSILs and carci-
nomas. Due to the heterogeneity of cytological samples this
could reﬂect diﬀerent pathways that are activated in speciﬁc
types of cells or could be due to the partial methylation that
can be identiﬁed with MSP but is not enough to abolish
protein expression [24]. MGMT methylation was correlated
with previously reported risk factors for severe lesions [7,
20, 21, 25], while interestingly enough hMLH1 methylation
was correlated with low-risk HPV types especially when co-
infection of a low-risk with a high-risk was identiﬁed.
4.Conclusion
Aberrant DNA promoter methylation of MGMT, hMLH1,
and p16INK4A is a common ﬁnding in liquid-based cytology
samples of the cervix. Even though, there is a statistically
signiﬁcant increase of DNA methylation as the severity of
the lesion increases, either for a single gene, or for the total
number of methylated genes, the accuracy of promoter
DNA methylation in identifying severe lesions is low. As a
result wide use in screening programs is not recommended,
since more studies with larger methylation panels should be
performed before the exact signiﬁcance of methylation in
cervical carcinogenesis is elucidated.
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